Absci is a generative AI drug creation company based in Vancouver, WA, that aims to revolutionize the biologics drug discovery process. Their innovative approach involves designing antibodies from scratch using zero-shot AI, which generates candidates unlike those found in existing databases. By combining AI with synthetic biology, Absci's Integrated Drug Creation platform enables the rapid development and validation of new biologic-based therapeutics, potentially reducing the time it takes to bring new drug leads into the clinic and unlocking treatments for traditionally undruggable diseases. Absci's breakthrough technology has garnered attention and partnerships from industry leaders, including Merck, AstraZeneca, EQRx, and Almirall, who recognize the potential of Absci's de novo AI antibody creation platform in designing novel therapies and addressing high unmet medical needs. With their powerful data generation and AI protein engineering platform, Absci is poised to disrupt the biopharmaceutical industry and create drugs at the speed of AI.Generated from the website

Puttman Infrastructure Inc

Alport, Marc Harris Agt

Glenn W Robles

Martin Sell AIA Rketek.com LLC